Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders

Author(s): D.S. Cha, M. Vahtra, J. Ahmed, P.A. Kudlow, R.B. Mansur, A.F. Carvalho, R.S. McIntyre

Journal Name: Current Molecular Medicine

Volume 16 , Issue 5 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Impairments in cognitive function represent a consistent, non-specific, and clinically significant feature in metabolic, mood, and dementing disorders. The foregoing observation is instantiated by evidence demonstrating that these disorders share pathophysiological mechanisms including, but not limited to, aberrant insulin signaling, inflammation, and glucocorticoid activity. Moreover, these mechanisms have been consistently reported to increase vulnerability to and/or exacerbate impairments in cognitive function. Notwithstanding evidence suggesting a bidirectional relationship between disturbances in the metabolic milieu, mood, and increased risk for dementia, efficacious treatments that target cognitive impairments in these populations do not presently exist. Taken together, it is proposed that anti-diabetic agents may aid the management of mood disorders and future risk for dementia through disease modification by targeting underlying pathophysiological mechanisms (e.g., aberrant metabolic function) rather than focusing solely on symptom mitigation. The current aim is to provide a brief narrative review of extant studies that report on the potential neurotherapeutic effects of anti-diabetic agents on disturbances in mood and impairments in cognitive function.

Keywords: Depression, bipolar, diabetes, dementia, Alzheimer’s disease, insulin, insulin resistance, GLP-1, incretin, thiazolidinedione, metformin, cognition.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 20 June, 2016
Page: [465 - 473]
Pages: 9
DOI: 10.2174/1566524016666160429121737
Price: $65

Article Metrics

PDF: 44